ArticleFrontiers in veterinary science2026
Sterility, safety, and preventive efficacy of three polyvalent hyperimmune sera against bacterial infection in a white mouse challenge model.
Article in Frontiers in veterinary science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Polyvalent hyperimmune sera are widely used for emergency passive immunoprophylaxis; however, controlled experimental evidence supporting their safety and preventive efficacy remains limited. Methods: In this study, three polyantigenic hyperimmune sera were evaluated using a standardized white mouse bacterial challenge model. Sera were generated through stepwise immunization of donor animals with monovalent and polyvalent antigenic formulations targeting enteric and respiratory pathogens. Sterility and safety were assessed prior to Results: Serological characterization confirmed robust virus- and bacteria-specific humoral responses in donor animals, with end-point antibody titers reaching up to 1:2560 in serum preparations containing viral antigens. All tested sera were sterile and well tolerated, with no adverse clinical effects observed during the monitoring period. Prophylactic administration led to a marked increase in survival compared with untreated controls across multiple bacterial challenge models, with absolute risk reduction values ranging from 40 to 100%. In contrast, native serum collected prior to immunization provided only partial or no protection. Discussion: Overall, these findings provide controlled experimental evidence demonstrating the safety, immunogenicity, and reproducible preventive efficacy of polyvalent hyperimmune sera in a murine bacterial infection model, supporting their consideration as candidate immunobiological agents for passive protection against bacterial infections under controlled experimental conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.